Afya (NASDAQ:AFYA – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.
A number of other brokerages have also recently issued reports on AFYA. UBS Group upgraded Afya from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $19.50 to $19.00 in a research note on Monday, September 8th. Weiss Ratings restated a “hold (c)” rating on shares of Afya in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upgraded shares of Afya from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $23.50 to $24.50 in a research note on Monday, September 8th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.75.
View Our Latest Research Report on AFYA
Afya Price Performance
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Militia Capital Partners LP purchased a new stake in Afya in the 2nd quarter worth $71,000. Quantbot Technologies LP purchased a new position in shares of Afya in the second quarter valued at about $117,000. Van ECK Associates Corp boosted its stake in shares of Afya by 15.7% in the third quarter. Van ECK Associates Corp now owns 10,170 shares of the company’s stock worth $159,000 after acquiring an additional 1,377 shares during the period. State of Wyoming purchased a new stake in shares of Afya during the second quarter worth about $164,000. Finally, Quadrature Capital Ltd bought a new stake in Afya during the 2nd quarter valued at approximately $181,000. 88.02% of the stock is currently owned by institutional investors.
Afya Company Profile
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Read More
- Five stocks we like better than Afya
- Retail Stocks Investing, Explained
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- How to Calculate Stock Profit
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
